Femasys Secures First Revenue from In-Office FemaSeed Fertility Solution
Femasys reported first revenue-generating commercial use of its fertility portfolio in OB/GYN setting via FemaSeed Complete, supported by FemSperm for intratubal insemination and in-office sperm preparation. The integrated solution addresses a treatment gap affecting an estimated 10 million U.S. women by offering earlier, lower-cost intervention outside specialized centers.
1. Commercial Milestone
Femasys recorded its first revenue-generating use of FemaSeed Complete in an OB/GYN practice, marking its entry into routine in-office fertility care. The procedure was enabled by FemSperm, facilitating integrated sperm preparation and intratubal insemination in a single visit.
2. Integrated In-Office Workflow
FemaSeed Complete combines intratubal insemination with CLIA-waived FemSperm sperm preparation, eliminating external lab referrals and streamlining procedural workflow, reducing cost and complexity compared with IVF.
3. Addressing Treatment Gaps
With infertility affecting an estimated 10 million U.S. women yet fewer than 1% treated at specialized centers, Femasys’ solution aims to expand access by delivering fertility interventions in women’s primary care settings.
4. Strategic Growth Outlook
Following earlier-than-expected FDA clearance and ACOG launch, Femasys plans to accelerate adoption across OB/GYN practices, leveraging the new model to drive revenue growth and patient-centered outcomes.